DOXOrubicin 75mg/m² Monotherapy

INDICATIONS FOR USE:

<table>
<thead>
<tr>
<th>INDICATION</th>
<th>ICD10</th>
<th>Regimen Code</th>
<th>Reimbursement Status</th>
</tr>
</thead>
<tbody>
<tr>
<td>Treatment of locally advanced unresectable or metastatic soft tissue sarcoma</td>
<td>C49</td>
<td>00500a</td>
<td>Hospital</td>
</tr>
</tbody>
</table>

TREATMENT:
The starting dose of the drugs detailed below may be adjusted downward by the prescribing clinician, using their independent medical judgement, to consider each patient's individual clinical circumstances.

DOXOrubicin is administered once every 21 days for 3-6 cycles or until disease progression or unacceptable toxicity develops.

Facilities to treat anaphylaxis MUST be present when the chemotherapy is administered.

<table>
<thead>
<tr>
<th>Day</th>
<th>Drug</th>
<th>Dose</th>
<th>Route</th>
<th>Diluent &amp; Rate</th>
<th>Cycle</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td><strong>DOXO</strong></td>
<td>75mg/m²</td>
<td>IV bolus</td>
<td></td>
<td>Every 21 days for 6 cycles</td>
</tr>
</tbody>
</table>

*a*Lifetime cumulative dose of DOXOrubicin is 450mg/m²

In establishing the maximal cumulative dose of an anthracycline, consideration should be given to the risk factors outlined below and to the age of the patient.

*b*Consider dose reduction to 60mg/m² in patients >70 years

ELIGIBILITY:

- Indication as above
- ECOG 0-2
- Adequate hepatic, renal, and bone marrow function

EXCLUSIONS:

- Hypersensitivity to DOXOrubicin or any of the excipients
- Congestive heart failure (LVEF < 50%) or other significant heart disease
- Pregnancy
- Lactation

PRESCRIPTIVE AUTHORITY:
The treatment plan must be initiated by a Consultant Medical Oncologist

TESTS:

Baseline tests:

The information contained in this document is a statement of consensus of NCCP and ISMO or IHS professionals regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult these documents is expected to use independent medical judgement in the context of individual clinical circumstances to determine any patient’s care or treatment. Use of these documents is the responsibly of the prescribing clinician, and is subject to HSE’s terms of use available at [http://www.hse.ie/eng/Disclaimer](http://www.hse.ie/eng/Disclaimer).

This information is valid only on the day of printing, for any updates please check [www.hse.ie/NCCPchemoregimens](http://www.hse.ie/NCCPchemoregimens).
NCCP Chemotherapy Regimen

- FBC, renal and liver profile
- Cardiac function using MUGA or ECHO (LVEF ≥ 50% to administer DOXOrubicin) if >65 years or if clinically indicated (e.g. smoking history, hypertension)

Regular tests:
- FBC, renal and liver profile prior to each cycle
- Cardiac function as clinically indicated

Disease monitoring:
Disease monitoring should be in line with the patient’s treatment plan and any other tests as directed by the supervising Consultant.

DOSE MODIFICATIONS:
- Any dose modification should be discussed with a Consultant.

Table 1: Dose reduction levels for DOXOrubicin

<table>
<thead>
<tr>
<th>Starting Dose</th>
<th>75mg/m²</th>
</tr>
</thead>
<tbody>
<tr>
<td>Level -1</td>
<td>60mg/m²</td>
</tr>
<tr>
<td>Level -2</td>
<td>50mg/m²</td>
</tr>
<tr>
<td>Level-3</td>
<td>Discontinue</td>
</tr>
</tbody>
</table>

Haematological:
Table 2: Dose modification of DOXOrubicin in haematological toxicity

<table>
<thead>
<tr>
<th>ANC (x10⁹ /L)</th>
<th>Platelets (x10⁹ /L)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>≥1 and ≥100</td>
<td></td>
<td>100%</td>
</tr>
<tr>
<td>&lt;1 or &lt;100</td>
<td></td>
<td>Delay one week or until recovery. If &gt; 2 week delay consider dose reduction by 1 dose level</td>
</tr>
</tbody>
</table>

Febrile neutropenia
1st occurrence
Reduce dose by one dose level
2nd occurrence
Consider addition of G-CSF to subsequent cycles

Renal and Hepatic Impairment:
Table 3: Dose modification of DOXOrubicin in renal and hepatic impairment

<table>
<thead>
<tr>
<th>Renal Impairment</th>
<th>Hepatic Impairment</th>
</tr>
</thead>
<tbody>
<tr>
<td>No dose reduction required. Clinical decision in severe impairment</td>
<td>Total Bilirubin (micromol/L)</td>
</tr>
<tr>
<td></td>
<td>20-50</td>
</tr>
<tr>
<td></td>
<td>51-85</td>
</tr>
<tr>
<td></td>
<td>&gt;85</td>
</tr>
<tr>
<td></td>
<td>AST 2-3 ULN give 75% of dose</td>
</tr>
<tr>
<td></td>
<td>AST &gt;3 ULN give 50% of dose</td>
</tr>
</tbody>
</table>

NCCP Regimen: DOXOrubicin 75mg/m² Monotherapy
Published: 13/08/2018
Review: 30/07/2025
Version number: 2

Tumour Group: Sarcoma
NCCP Regimen Code: 00500a
IHS/ISMO Contributor: Dr Michael McCarthy, Prof Maccon Keane
Page 2 of 4

The information contained in this document is a statement of consensus of NCCP and ISMO or IHS professionals regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult these documents is expected to use independent medical judgement in the context of individual clinical circumstances to determine any patient’s care or treatment. Use of these documents is the responsibly of the prescribing clinician, and is subject to HSE’s terms of use available at http://www.hse.ie/eng/Disclaimer

This information is valid only on the day of printing, for any updates please check www.hse.ie/NCCPchemoregimens
Management of adverse events:

Table 4: Dose Modification of DOXOrubicin for Adverse Events

<table>
<thead>
<tr>
<th>Adverse reactions</th>
<th>Recommended dose modification</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cardiotoxicity:</td>
<td>Treatment should be discontinued if absolute LVEF &lt;45% or &gt;20% reduction in baseline LVEF</td>
</tr>
<tr>
<td>Other grade 3-4 toxicities</td>
<td>Hold chemotherapy until toxicity improves to grade ≤1. Consider dose reduction by 1 dose level.</td>
</tr>
</tbody>
</table>

SUPPORTIVE CARE:

EMETOGENIC POTENTIAL: High (Refer to local policy).

PREMEDICATIONS: None usually required

OTHER SUPPORTIVE CARE:
No specific recommendations

ADVERSE EFFECTS / REGIMEN SPECIFIC COMPLICATIONS

The adverse effects listed are not exhaustive. Please refer to the relevant Summary of Product Characteristics for full details.

- **Neutropenia**: Fever or other evidence of infection must be assessed promptly and treated appropriately.
- **Cardiotoxicity**: DOXOrubicin is cardiotoxic and must be used with caution, if at all, in patients with severe hypertension or cardiac dysfunction
- **Extravasation**: DOXOrubicin causes pain and tissue necrosis if extravasated (Refer to local policy).

DRUG INTERACTIONS:

- DOXOrubicin cardiotoxicity is enhanced by previous or concurrent use of other anthracyclines, or other potentially cardiotoxic drugs (e.g. 5-Fluorouracil, cyclophosphamide or PACLitaxel) or with products affecting cardiac function (e.g. calcium antagonists).
- Current drug interaction databases should be consulted for more information.

ATC CODE:

DOXOrubicin L01DB01

REFERENCES:

2. University College London. GeDDIS: A prospective randomised controlled phase III trial of gemcitabine and docetaxel compared with doxorubicin as first line treatment in previously untreated advanced...
unresectable or metastatic soft tissue sarcomas [Internet]. Available from: https://www.ctc.ucl.ac.uk/TrialDocuments/Uploaded/GeDDiS%20Protocol%20v8.0%2022Mar2016_06062017_0.pdf


<table>
<thead>
<tr>
<th>Version</th>
<th>Date</th>
<th>Amendment</th>
<th>Approved By</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>13/08/2018</td>
<td></td>
<td>Dr Michael McCarthy</td>
</tr>
<tr>
<td>2</td>
<td>30/07/2020</td>
<td>Updated eligibility criteria</td>
<td>Prof Maccon Keane</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Updated exclusion criteria</td>
<td></td>
</tr>
</tbody>
</table>

Comments and feedback welcome at oncologydrugs@cancercontrol.ie.

1 Cardiotoxicity is a risk associated with anthracycline therapy that may be manifested by early (acute) or late (delayed) effects. Risk factors for developing anthracycline-induced cardiotoxicity include:
• high cumulative dose, previous therapy with other anthracyclines or anthracenediones
• prior or concomitant radiotherapy to the mediastinal/pericardial area
• pre-existing heart disease
• concomitant use of other potentially cardiotoxic drugs

In establishing the maximal cumulative dose of an anthracycline, consideration should be given to the risk factors above and to the age of the patient.